Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases.
Our two lead assets are Bevyxxa¬ (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs.
We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
- Company Name:Portola Pharmaceuticals
(View Trends)
-
Headquarters: (View Map)South San Francisco, CA, United States
-
200 - 500 employees
- 3334245 Global Rank
- 1260546 United States
-
Direct59.11%
-
Search30.65%
-
Referrals10.24%
-
Display0.00%
-
Mail0.00%
-
Social0.00%
- United States 91.7%
- Deutsch
- Medien
- Fernsehen
- Sender
- 50 Downloads
- 10 SDKs
- 0 Total reviews
- App Url: https://play.google.com/store/apps/details?id=com.portola.spektapp.seamonsters
- App Support:
- Genre: education
- Bundle ID: com.portola.spektapp.seamonsters
- App Size: 73.9 M
- Release Date: December 16th, 2018
- Update Date: December 17th, 2018
Description:
Monsters of the Sea is a comprehensive educational exhibition that plunge visitors in a journey to the past of the aquatic world. Each monster features life-like movements, colors and textures, delivering unique “real life” encounters with these massive creatures.
Our team of scientific experts designed the layout of the exhibition with careful consideration for even the smallest factual details. Illustrated displays and informational panels provide instructional and educational material for visitors of all ages.
-
Standard100.00%
-
Direct0.00%